Clinical Report: Stockholm3 Prostate Cancer Test Outperforms PSA Screening
Overview
The Stockholm3 test detected over twice as many clinically significant prostate cancers compared to age-based PSA screening in a study involving 12,670 men. This multivariable blood test demonstrated a higher detection rate while maintaining similar false-positive rates.
Background
Prostate cancer screening is critical for early detection and treatment, particularly for clinically significant cases. Traditional PSA screening has limitations, including lower sensitivity and specificity.
Data Highlights
Test
Clinically Significant Cancers Detected
False Positive Rate
Stockholm3
400
11%
PSA ≥3 ng/ml
327
10%
PSA ≥4 ng/ml
231
5%
Key Findings
Stockholm3 identified 90% of clinically significant prostate cancers compared to 74% for PSA ≥3 ng/ml.
The false-positive rate for Stockholm3 was comparable to PSA ≥3 ng/ml, but higher than PSA ≥4 ng/ml.
Decision-curve analyses indicated a higher overall clinical benefit for Stockholm3 across various biopsy decision thresholds.
Stockholm3 referred more men for additional diagnostic assessments than conventional PSA screening.
The study involved a population-based analysis of men aged 50 to 74 years in Sweden.
Clinical Implications
Clinicians should consider the increased referral rates for diagnostic assessments associated with this test.
Conclusion
The Stockholm3 test shows potential in enhancing prostate cancer detection compared to traditional PSA screening.
